FDA has taken steps to embrace AI in 2025, announcing in December that it will be providing agency staff with agentic AI ...

The FDA has qualified AI-Based Histologic Measurement of MASH, or AIM-MASH AI Assist — the first AI drug development tool — ...

The world of medicine has taken a significant leap forward with the first AI-generated drug entering clinical trials. This breakthrough has the potential to revolutionize drug discovery, transforming ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued ...

UB researcher Murali Ramanathan has used artificial intelligence (AI) since its nascent days while exploring possible treatments for multiple sclerosis (MS) and Alzheimer’s disease. Today, Ramanathan, ...

Insilico Medicine Cayman TopCo, an AI drug discovery startup, jumped in its trading debut in Hong Kong as the financial hub ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...

AI-leveraged drug development has become an $18 billion industry, but companies in the sector are experiencing some hardships. Beyond efforts to convenience investors their drugs are safe and ...

Large pharmaceutical companies are entering a period of renewed relevance as therapeutic innovation accelerates, particularly ...